Qube Pharma Group

Name

Qube Pharma Group

Legal name

Grupo Geiser Pharma, S.L.

Website

https://qubepharmagroup.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Generic pharmaceuticals
• OTC medications
• Medical device manufacturing
• Oncology pharmaceuticals
• Pharmaceutical research

Headquarters

HQ city

Pamplona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Distribution channels1 record

Core offering

Qube Pharma Group is a Spanish pharmaceutical holding company that conducts research, development, and manufacture of value-added pharmaceutical products through four subsidiary companies. Its product portfolio spans niche generic products, over-the-counter (OTC) products, and CE-marked medical devices, marketed internationally across 45 countries. The group also maintains a dedicated fund that invests in innovative emerging pharmaceutical companies.

Product overview

Qube Pharma Group is a pharmaceutical group founded in 2007 consisting of 4 subsidiary companies engaged in research, development, and manufacture of value-added pharmaceutical products. The group operates across three main product categories: Niche Generic Products, OTC Products, and CE-marked Medical Devices. The four subsidiaries include Geiser Pharma (innovative pharmaceuticals, Pamplona), Proteus Pharma (oncology and cancer pain treatment, Barcelona), LozYs Pharma (medicated lozenges manufacturing, Navarra), and Sejmet Pharmaceuticals (niche generics, Italian market focus). The group has international presence marketing products in 45 countries and also invests in innovative emerging pharmaceutical companies through a dedicated investment fund.

Differentiator

Problem solved

Functional benefit

Products and services

• Niche Generic Products
• OTC Products
• CE-marked Medical Devices
• Medicated Lozenges Manufacturing Contract development, production, and packaging of medicated lozenges (caramelos medicalizados) for third parties, manufactured at LozYs Pharma's 4000 m2 production plant in the North of Navarra built in 2015.
• Oncology Pharmaceuticals Innovative, high-technology pharmaceutical products for the oncology field with a special focus on treatment of widespread pain in cancer patients, developed by Proteus Pharma based in Barcelona.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core.

• Geiser PharmacoreStrategic or Co-development PartnerSubsidiary company of Qube Pharma Group, headquartered in Pamplona (Navarra), created in 2008, devoted to development and commercialisation of innovative pharmaceuticals with comprehensive management covering all stages of the pharmaceutical value chain.
• Proteus PharmacoreStrategic or Co-development PartnerSubsidiary pharmaceutical company headquartered in Barcelona, specialising in research and development of innovative high-technology products for oncology, with special focus on treatment of widespread pain in cancer patients.
• LozYs PharmacoreStrategic or Co-development Partner4000 m2 production plant in the North of Navarra, built in 2015, equipped with latest technology for development, production and packaging of medicated lozenges for third parties.
• Sejmet PharmaceuticalscoreStrategic or Co-development PartnerPharmaceutical company focused on research and development of value-added products in the niche generic segment, with special focus on the Italian market among others.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Almirall: Barcelona-based specialty pharmaceutical company focused on medical dermatology and general medicine. Comparable to Qube through its Barcelona-based Proteus Pharma subsidiary and similar specialty-pharma positioning in European markets.
• Faes Farma: Spanish mid-cap pharmaceutical group with a portfolio spanning prescription, OTC, and consumer healthcare products across multiple geographies. Comparable to Qube in scale, Iberian base, and mix of branded pharma and OTC.
• Kern Pharma: Spanish generics manufacturer and part of Grupo Indukern, with a broad portfolio of generic and biosimilar products. Directly comparable to Sejmet Pharmaceuticals' niche-generics focus and Qube's Spanish manufacturing base.
• Medochemie: Cyprus-headquartered, privately-held European generics manufacturer with products sold in more than 100 countries. Comparable to Qube as a privately-held European pharma group with broad international generics distribution.
• Italfarmaco: Privately-held Italian pharmaceutical group with international reach, active in specialty pharma, rare diseases, and women's health. Highly comparable to Qube as a privately-controlled European pharma group of similar scale and international distribution model.
• Laboratorios Normon: Spanish family-owned generics manufacturer with vertically integrated production and broad European reach. Comparable to Qube's privately-held structure, Spanish manufacturing base, and focus on generics and value-added formulations.
• Laboratorios Rovi: Spanish specialty pharmaceutical company listed on the Madrid stock exchange, focused on value-added proprietary products including niche generics, biosimilars, and CDMO services. Closely comparable to Qube in geographic base, specialty-generics orientation, and contract manufacturing exposure.
• Recordati: Italian specialty pharmaceutical group with presence in niche primary care, rare diseases, and self-medication across Europe. Comparable to Qube in pan-European specialty distribution, primary-care focus, and OTC exposure.

Broad incumbents

• Stada Arzneimittel: Large European-focused generics and consumer healthcare company owned by Bain Capital, with pan-European distribution. Broader incumbent comparable to Qube in generics-plus-consumer-health positioning, but at significantly greater scale.
• Teva Pharmaceutical Industries: Global leader in generic pharmaceuticals headquartered in Israel, with operations across Europe and a broad specialty pharma franchise. Broad incumbent relevant for benchmarking Qube's generic-segment economics and competitive dynamics, though materially larger in scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qube Pharma Group